Business
Alnylam to Present Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the American Academy of Neurology Virtual Annual Meeting 2021
– Alnylam to Share Additional Data From its RNAi Product Portfolio Including ATTR Amyloidosis and Acute Hepatic Porphyria – –Company to Host Conference Call
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"text","content":"\n– Alnylam to Share Additional Data From its RNAi Product Portfolio Including ATTR Amyloidosis and Acute Hepatic Porphyria – \n\n–Company to Host Conference Call April 19th at 4:00 pm ET to Discuss HELIOS-A Results –\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present full 9-month results from the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of the polyneuropathy of hereditary ATTR (hATTR) amyloidosis, at the American Academy of Neurology (AAN) Virtual Annual Meeting, being held April 17-22. The Company previously announced positive topline 9-month results from the HELIOS-A study in January. Additional data from Alnylam’s ATTR amyloidosis program, including updates from the ongoing open-label extension study of ONPATTRO (patisiran) in patients with hATTR amyloidosis with polyneuropathy, will also be presented at AAN, along with data from the Phase 3 ENVISION study of GIVLAARI in patients with acute hepatic porphyria (AHP).\n\n“The depth and breadth of data that will be presented at AAN from across our RNAi product and pipeline portfolio reinforce the tremendous progress we have made with developing potentially transformative medicines for patients with rare diseases,” said Akshay Vaishnaw, M.D., Ph.D., President of R&D at Alnylam. “In January we announced positive topline results from the HELIOS-A Phase 3 study of vutrisiran, the fifth of our investigational RNAi medicines to reach that significant milestone. We are excited for the upcoming presentation of the full 9-month HELIOS-A results as we believe in the potential of vutrisiran, as a low-dose, once quarterly, subcutaneously administered treatment option for patients living with a progressive, life-threatening, multi-system disease. We look forward to submitting our U.S. regulatory filing for marketing approval of vutrisiran in early 2021 as we continue to make progress towards building what we believe will be an industry-leading franchise of medicines for the treatment of ATTR amyloidosis.”\n\nhATTR Amyloidosis\n\n\nHELIOS-A: 9-month Results from the Phase 3 Study of Vutrisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy\nOral Presentation\nMonday, April ...